State of the Science Summit on Hematologic Malignancies | Conference

Ruxolitinib Combos Explored to Address MPN-Associated Symptoms

May 6th 2019

Laura Michaelis, MD, highlights the many ruxolitinib combinations under investigation and provided insight into the role of interferon in myeloproliferative neoplasms.

Dr. Dhakal on Early Data With BiTEs in Multiple Myeloma

May 3rd 2019

Binod Dhakal, MD, assistant professor, Medical College of Wisconsin, discusses early data with bispecific T-cell engager (BiTE) antibody constructs in multiple myeloma.

MCL Treatment Paradigm Expands With Novel Combos

May 1st 2019

Timothy Fenske, MD, MS, discusses promising ongoing research in mantle cell lymphoma that will look to further advanced the evolving paradigm.

Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL

April 21st 2019

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses his recommendations for oncologists treating patients with mantle cell lymphoma (MCL) who are progressing on ibrutinib (Imbruvica).

Dr. Alderuccio on the Use of Proteasome Inhibitors in Frontline Myeloma

April 17th 2019

Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.

Dr. Lossos on Research Questions in MCL

April 5th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses research questions in the field of mantle cell lymphoma (MCL).

Eltrombopag Fills Unmet Need in Hematologic Disorders, But More Work Remains

April 5th 2019

Alvaro Jose Alencar, MD, highlights advances made in the treatment of patients with hematologic disorders, offers advice on how to choose between available agents, and sheds light on future research.

Novel Therapies Reduce Symptom Burden, Result in Improved Survival in MPNs

April 4th 2019

Terrence J. Bradley, MD, discusses approved and investigational agents that patients with myelofibrosis and polycythemia vera can turn to.

Dr. Lekakis on Real-World Data With CAR T-Cell Therapy in Lymphoma

April 2nd 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses real-world data with CAR T-cell therapy from the 2018 ASH Annual Meeting.

Dr. Hoffman on Anticipated Developments in Multiple Myeloma

April 2nd 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses anticipated developments in the field of multiple myeloma.

Emerging Treatments in Multiple Myeloma Spark Prospect for Cure

March 26th 2019

James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.

CAR T Cells Bring Promise to Patients With ALL, DLBCL With Poor Prognosis

March 26th 2019

Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.

Moskowitz Weighs Benefits, Challenges With A+AVD in Hodgkin Lymphoma

March 25th 2019

Craig Moskowitz, MD, discusses the role of PET imaging in the treatment of patients with Hodgkin lymphoma, weighs the pros and cons of A+AVD, and speaks to where future research is headed in the space.

AML Armamentarium Expands, Offering Hope for Consistent Cure

March 25th 2019

Justin M. Watts, MD, sheds light on these promising agents and their impact in the space, discusses remaining challenges, and expresses his hope for an era where most patients with acute myeloid leukemia will be cured.

Nimer Highlights Treatment Trends Across Hematologic Malignancies

March 25th 2019

Stephen D. Nimer, MD, sheds light on new strategies and trends in the treatment of patients with hematologic malignancies.

Despite Progress in Follicular Lymphoma and MCL, Critical Questions Remain

March 20th 2019

Izidore S. Lossos, MD, discusses the current pillars of care and barriers in the treatment of patients with early-stage and advanced follicular lymphoma, as well as mantle cell lymphoma.

Dr. Nimer on CAR T-Cell Therapy in Hematologic Malignancies

March 19th 2019

Stephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Dr. Lossos on Treatment Approaches in MCL

March 19th 2019

Izidore S. Lossos, MD, professor, director, Lymphoma Program Head of hematological malignancies site disease group, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses treatment approaches for patients with mantle cell lymphoma (MCL).

Dr. Lekakis on Current Research With CAR T-Cell Therapy

March 15th 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses current research with chimeric antigen receptor (CAR) T-cell therapy across hematologic malignancies.

Dr. Vij on Maintenance and Consolidation in Newly Diagnosed Multiple Myeloma

November 9th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.